{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:40Z","timestamp":1790609560262,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-021-02058-y","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T17:02:39Z","timestamp":1623085359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization"],"prefix":"10.1208","volume":"22","author":[{"given":"Nimrat","family":"Khehra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir","family":"Padda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Jaferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshan","family":"Atwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-9857","authenticated-orcid":false,"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2058_CR1","unstructured":"WHO. Coronavirus disease COVID-19. WHO coronavirus disease (COVID-19) dashboard. World Health Organization. April 9, 2021, [Accessed April 19, 2021 https:\/\/covid19.who.int\/]"},{"key":"2058_CR2","doi-asserted-by":"publisher","unstructured":"Sahin U, Muik A, Derhovanessian E, et al. Concurrent human antibody and TH1 type T-cell responses 2 elicited by a COVID-19 RNA vaccine. medRxiv. Published July 20, 2020. doi: https:\/\/doi.org\/10.1101\/2020.07.17.20140533. [Accessed January 14, 2020, https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.17.20140533v1].","DOI":"10.1101\/2020.07.17.20140533"},{"key":"2058_CR3","doi-asserted-by":"publisher","unstructured":"Vogel AB, Kanevsky I, Che Y, et al. Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2 [published online ahead of print, 2021 Feb 1]. Nature. 2021;10.1038\/s41586-021-03275-y. doi:https:\/\/doi.org\/10.1038\/s41586-021-03275-y [Accessed February 2, 2021 https:\/\/www.nature.com\/articles\/s41586-021-03275-y]","DOI":"10.1038\/s41586-021-03275-y"},{"key":"2058_CR4","unstructured":"Pfizer. n.d. News\/Pfizer and BionTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal phase 2\/3 global study. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0"},{"issue":"25","key":"2058_CR5","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2027906 [Accessed April 6, 2021 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2027906].","journal-title":"N Engl J Med"},{"key":"2058_CR6","unstructured":"Padda IS, Parmar M. COVID (SARS-COV-2) Vaccine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 16, 2021. [Accessed April 11, 2021 https:\/\/pubmed.ncbi.nlm.nih.gov\/33620862\/ ]"},{"key":"2058_CR7","doi-asserted-by":"publisher","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine [published online ahead of print, 2020 December 10]. N Engl J Med. 2020;10.1056\/NEJMoa2034577. doi:https:\/\/doi.org\/10.1056\/NEJMoa2034577 [Accessed January 14, 2021 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2034577]","DOI":"10.1056\/NEJMoa2034577"},{"key":"2058_CR8","unstructured":"Pfizer. Pfizer and BioNTech announce publication of results from landmark phase 3 trial of BNT162b2 COVID-19 vaccine candidate in the New England Journal of Medicine. [Accessed April7th,2021https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-announce-publication-results-landmark ]"},{"key":"2058_CR9","doi-asserted-by":"publisher","unstructured":"Choi KR. A nursing researcher\u2019s experience in a COVID-19 vaccine trial. JAMA Intern Med. Published online December 07, 2020. doi:https:\/\/doi.org\/10.1001\/jamainternmed.2020.7087 [Accessed December 18, 2020, https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2773790], 157, 158","DOI":"10.1001\/jamainternmed.2020.7087"},{"key":"2058_CR10","unstructured":"GOV. U.K. Regulatory approval of Pfizer\/BioNTech vaccine for COVID-19. [Accessed December 18, 2020,] https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19]"},{"key":"2058_CR11","doi-asserted-by":"publisher","unstructured":"Nature. The U.K. has approved a COVID vaccine \u2014 here\u2019s what scientists now want to know. ISSN 1476-4687 Nature 588, 205-206 (2020) doi: https:\/\/doi.org\/10.1038\/d41586-020-03441-8 [Accessed December 18, 2020 https:\/\/www.nature.com\/articles\/d41586-020-03441-8","DOI":"10.1038\/d41586-020-03441-8"},{"key":"2058_CR12","unstructured":"Government of Canada. Pfizer-BioNTech COVID-19 vaccine: what you should know. COVID-19 vaccines [Accessed December 18, 2020,] https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/pfizer-biontech.html"},{"key":"2058_CR13","unstructured":"Government of Canada. Pfizer-BioNTech COVID-19 vaccine (tozinameran). COVID-19 vaccines and treatments portal [Accessed December 18, 2020 ]https:\/\/covid-vaccine.canada.ca\/pfizer-biontech-covid-19-vaccine\/product-details"},{"key":"2058_CR14","unstructured":"CDC. Morbidity and mortality weekly report (MMWR). Weekly\/December 18, 2020\/69(50);1922-1924 [Accessed December 18, https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6950e2.htm?s_cid=mm6950e2_x]"},{"key":"2058_CR15","unstructured":"FDA. Pfizer-BioNTech COVID-19 vaccine [Accessed December 18, 2020 ]https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccine"},{"key":"2058_CR16","unstructured":"Pfizer. News\/Pfizer and BioNTech receive authorization in the European Union for COVID-19 vaccine [Accessed January 14, 2021 https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-receive-authorization-european-union#:~:text=(NYSE%3A%20PFE)%20and%20BioNTech,16%20years%20of%20age%20and"},{"key":"2058_CR17","unstructured":"Pfizer. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents. [Accessed April 7, 2021 https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-biontech-announce-positive-topline-results-pivotal]"},{"key":"2058_CR18","unstructured":"Clinicaltrials.gov. A phase 3 study to evaluate the safety, tolerability, and immunogenicity of multiple production lots and dose levels of BNT162b2 against COVID-19 in healthy participants. [Accessed April 11, 2021 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04713553 ]"},{"key":"2058_CR19","unstructured":"Pfizer. Studies in additional populations. [April 7, 2021 https:\/\/www.pfizer.com\/science\/coronavirus\/vaccine\/additional-population-studies ]"},{"key":"2058_CR20","unstructured":"Clinicaltrials.gov. Study to evaluate the safety, tolerability, and immunogenicity of an RNA vaccine candidate against COVID-19 in healthy children <12 years of age [Accessed April 11, 2021 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04816643]"},{"key":"2058_CR21","unstructured":"Pfizer. Real-world evidence confirms high effectiveness of Pfizer and BioNTech COVID-19 vaccine and profound public health impact of vaccination one week after pandemic declared. [Accessed April 8, 2021 https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/real-world-evidence-confirms-high-effectiveness-pfizer]"},{"key":"2058_CR22","doi-asserted-by":"publisher","unstructured":"Iacobucci G. COVID-19: single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest. BMJ. 2021;372:n612 doi:10.1136\/bmj.n612, Accessed 17 Apr 2021. https:\/\/doi.org\/10.1136\/bmj.n612.","DOI":"10.1136\/bmj.n612"},{"issue":"4","key":"2058_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/vaccines904036","volume":"9","author":"M Jahn","year":"2021","unstructured":"Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-H\u00e4dicke B, Tyczynski B, et al. Humoral response to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines. 2021;9(4):360. Accessed Apr 17, 2021. https:\/\/doi.org\/10.3390\/vaccines904036.","journal-title":"Vaccines"},{"key":"2058_CR24","doi-asserted-by":"publisher","unstructured":"Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021; 397 (10279): P1057-1058. DOI:https:\/\/doi.org\/10.1016\/S0140-6736(21)00501-8. [Accessed April 19, 2021, https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00501-8\/fulltext].","DOI":"10.1016\/S0140-6736(21)00501-8"},{"key":"2058_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372\u20134. https:\/\/doi.org\/10.1056\/NEJMc2101667 Accessed April 19, 2021, https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2101667.","journal-title":"N Engl J Med"},{"key":"2058_CR26","doi-asserted-by":"publisher","unstructured":"Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021. https:\/\/doi.org\/10.1038\/s41591-021-01325-6 Accessed April 19, 2021, https:\/\/www.nature.com\/articles\/s41591-021-01325-6.","DOI":"10.1038\/s41591-021-01325-6"},{"key":"2058_CR27","unstructured":"Gov.UK. Optimising the COVID-19 vaccination programme for maximum short-term impact. Updated January 26, 2021. Accessed 18 Apr, 2021 https:\/\/www.gov.uk\/government\/publications\/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement\/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact]"},{"key":"2058_CR28","unstructured":"Jones NK, Rivett L, Seaman S, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection [published online ahead of print, 2021 Apr 8]. Elife. 2021;10:e68808. Accessed Apr 11, 2021, https:\/\/elifesciences.org\/articles\/68808]"},{"key":"2058_CR29","doi-asserted-by":"crossref","unstructured":"Chodick G, Tene L, Patalon T, Gazit S, et al. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv. Preprint posted online January 29, 2021. Accessed Apr 18, 2021 https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.27.21250612v1]","DOI":"10.1101\/2021.01.27.21250612"},{"key":"2058_CR30","doi-asserted-by":"crossref","unstructured":"Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of \u2018real-world\u2019 vaccination outcomes from Israel. medRxiv. Preprint posted online February 3, 2021. Accessed Apr 18, 2021 https:\/\/www.medrxiv.org\/content\/10.1101\/2021.02.01.21250957v1#disqus_thread]","DOI":"10.1101\/2021.02.01.21250957"},{"issue":"10277","key":"2058_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0140-6736(21)00455-4","volume":"397","author":"JFR Robertson","year":"2021","unstructured":"Robertson JFR, Sewell HF, Stewart M. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? Lancet. 2021;397(10277):879\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)00455-4 Accessed April 17, 2021, https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00455-4\/fulltext.","journal-title":"Lancet"},{"key":"2058_CR32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27:620\u20131. https:\/\/doi.org\/10.1038\/s41591-021-01270-4 Accessed April 19, 2021 https:\/\/www.nature.com\/articles\/s41591-021-01270-4?s=08.","journal-title":"Nat Med"},{"key":"2058_CR33","doi-asserted-by":"publisher","unstructured":"Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN Study). Lancet. 2021. https:\/\/doi.org\/10.2139\/ssrn.3790399 Accessed April 19, 2021 https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3790399.","DOI":"10.2139\/ssrn.3790399"},{"issue":"6534","key":"2058_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.abg6105","volume":"371","author":"A Muik","year":"2021","unstructured":"Muik A, Wallisch A, Sanger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine\u2013elicited human sera. Science. 2021;371(6534):1152\u20133. https:\/\/doi.org\/10.1126\/science.abg6105 Accessed April 19, 2021 https:\/\/science.sciencemag.org\/content\/371\/6534\/1152.abstract.","journal-title":"Science"},{"key":"2058_CR35","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466\u20138. https:\/\/doi.org\/10.1056\/NEJMc2102017 Accessed April 19, 2021, https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2102017.","journal-title":"N Engl J Med"},{"key":"2058_CR36","doi-asserted-by":"publisher","unstructured":"Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. Published online January 21, 2021. doi:https:\/\/doi.org\/10.1001\/jama.2021.0600 [Accessed January 21, 2021 https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2775646?guestAccessKey=1441aa96-9dc6-4d50-85f8-8dcbd270a551&utm_source=linkedin_company&utm_medium=social_jama&utm_term=4423373747&utm_campaign=article_alert&linkId=109655018 ]","DOI":"10.1001\/jama.2021.0600"},{"key":"2058_CR37","doi-asserted-by":"publisher","unstructured":"McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases [published online ahead of print, 2021 Apr 7]. J Am Acad Dermatol. 2021;S0190-9622(21)00658-7. doi:https:\/\/doi.org\/10.1016\/j.jaad.2021.03.092 [Accessed April 11, 2021, https:\/\/pubmed.ncbi.nlm.nih.gov\/33838206\/]","DOI":"10.1016\/j.jaad.2021.03.092"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-02058-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:32:59Z","timestamp":1744072379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-02058-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["2058"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-02058-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"172"}}